Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACST Acasti Pharma	$2.87 -6.5%	$3.31	$1.72 ▼ $3.84	$28.86M	1.49	27,015 shs	19,767 shs
APHB Ampliphi Biosciences	$2.67 +4.7%	$0.00	$0.15 ▼ $1.37	$89.20M	N/A	842,200 shs	9,559 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACST Acasti Pharma	-6.21%	-15.71%	-15.59%	+17.62%	+1.66%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACST Acasti Pharma	2.4787 of 5 stars	3.5	5.0	0.0	0.0	0.6	0.8	1.3
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACST Acasti Pharma	3.00	Buy	$6.00	109.06% Upside
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest BOT, APHB, and ACST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
2/7/2024	ACST Acasti Pharma	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 4/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACST Acasti Pharma	N/A	N/A	N/A	N/A	$9.14 per share	N/A
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACST Acasti Pharma	-$42.43M	-$5.08	N/A	N/A	N/A	N/A	-13.18%	-11.32%	6/28/2024 (Estimated)
APHB Ampliphi Biosciences	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest BOT, APHB, and ACST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/12/2024	12/31/2023	ACST Acasti Pharma	-$0.23	-$0.21	+$0.02	-$0.21	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACST Acasti Pharma	N/A	N/A	N/A	N/A	N/A
APHB Ampliphi Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACST Acasti Pharma	N/A	15.19	15.19
APHB Ampliphi Biosciences	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ACST Acasti Pharma	6.08%
APHB Ampliphi Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ACST Acasti Pharma	13.51%
APHB Ampliphi Biosciences	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACST Acasti Pharma	32	9.40 million	8.13 million	Not Optionable
APHB Ampliphi Biosciences	30	33.47 million	N/A	Not Optionable

BOT, APHB, and ACST Headlines

Source	Headline
	Pacific Biosciences Stock (NASDAQ:PACB), Analyst Ratings, Price Targets, Predictions benzinga.com - October 24 at 10:52 PM
	Aphb Colony Pin Code indiatvnews.com - July 26 at 8:42 PM
	Aphb Colony Moulali Pin Code indiatvnews.com - February 26 at 7:37 AM
	Akston Biosciences Strengthens Board with Addition of John T. Preston finance.yahoo.com - January 25 at 8:36 PM
	Selecta Biosciences Stock (NASDAQ:SELB), Quotes and News Summary benzinga.com - January 5 at 5:43 PM
	APHB: Case Study on AB-PA01 Presented at ISHLT Annual Meeting finance.yahoo.com - October 27 at 12:59 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

UiPath Cuts Q1 and Raises Full Year Guidance
March 26, 2024 7:41 AM
View UiPath Cuts Q1 and Raises Full Year Guidance
PayPal Appears to Have Bottomed, is it Time to Buy?
March 22, 2024 9:11 AM
View PayPal Appears to Have Bottomed, is it Time to Buy?
Nike Stock and the 30% Rally That's Expected
March 22, 2024 9:45 AM
View Nike Stock and the 30% Rally That's Expected
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
March 28, 2024 9:25 AM
View Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Intuitive Machines: Charting a Course Among the Stars
March 21, 2024 11:30 AM
View Intuitive Machines: Charting a Course Among the Stars

All Headlines

Company Descriptions

Acasti Pharma

NASDAQ:ACST

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Ampliphi Biosciences

NYSEAMERICAN:APHB

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial